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BACKGROUND: Myocardial infarction (MI) is a leading cause of heart 
failure and death worldwide. Preservation of contractile function and 
protection against adverse changes in ventricular architecture (cardiac 
remodeling) are key factors to limiting progression of this condition to 
heart failure. Consequently, new therapeutic targets are urgently required 
to achieve this aim. Expression of the Runx1 transcription factor is 
increased in adult cardiomyocytes after MI; however, the functional role of 
Runx1 in the heart is unknown.
METHODS: To address this question, we have generated a novel 
tamoxifen-inducible cardiomyocyte-specific Runx1-deficient mouse. 
Mice were subjected to MI by means of coronary artery ligation. Cardiac 
remodeling and contractile function were assessed extensively at the 
whole-heart, cardiomyocyte, and molecular levels.
RESULTS: Runx1-deficient mice were protected against adverse 
cardiac remodeling after MI, maintaining ventricular wall thickness 
and contractile function. Furthermore, these mice lacked eccentric 
hypertrophy, and their cardiomyocytes exhibited markedly improved 
calcium handling. At the mechanistic level, these effects were achieved 
through increased phosphorylation of phospholamban by protein kinase 
A and relief of sarco/endoplasmic reticulum Ca2+-ATPase inhibition. 
Enhanced sarco/endoplasmic reticulum Ca2+-ATPase activity in Runx1-
deficient mice increased sarcoplasmic reticulum calcium content 
and sarcoplasmic reticulum–mediated calcium release, preserving 
cardiomyocyte contraction after MI.
CONCLUSIONS: Our data identified Runx1 as a novel therapeutic target 
with translational potential to counteract the effects of adverse cardiac 
remodeling, thereby improving survival and quality of life among patients 
with MI.
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Acute coronary artery blockage leading to pro-longed ischemia and subsequent cardiomyo-cyte death (myocardial infarction [MI]) initiates 
a reparative process in the heart that is associated with 
the generation of regional infarct tissue composed 
predominately of fibrillar collagens. The surviving car-
diomyocytes undergo eccentric hypertrophy, a process 
characterized by cardiomyocyte elongation with re-
duced diameter and impaired calcium handling, in par-
ticular decreased sarcoplasmic reticulum (SR)–mediated 
calcium uptake.1 These cellular changes are fundamen-
tal to adverse cardiac remodeling, which manifests 
clinically as left ventricular (LV) wall thinning, dilation, 
and reduced contractility.2 Together with neurohumoral 
activation, adverse cardiac remodeling after MI leads 
to the clinical syndrome of systolic heart failure, which, 
despite optimized medical therapy, is associated with 
extremely high mortality rates.3 Novel therapeutic strat-
egies to preserve LV contractile function and to limit 
adverse cardiac remodeling are therefore urgently re-
quired to treat patients with MI and to improve survival 
rates and quality of life.
The Runx gene family (RUNX1, RUNX2, and RUNX3) 
encodes DNA-binding α subunits that partner core bind-
ing factor β to form heterodimeric transcription factors.4 
RUNX proteins act as both activators and repressors of 
target genes in normal development and disease states.4 
To date, most research has focused on the role of RUNX1 
in hematopoiesis owing to the frequent involvement of 
this gene in leukemic translocations.4 In contrast, little 
was known about the role of Runx1 in the heart. This 
discrepancy is not surprising given that although Runx1 
expression is reported in neonatal cardiomyocytes, it de-
creases to minimal levels in adult cardiomyocytes.5,6 How-
ever, studies have demonstrated that Runx1 is reactivated 
in cardiomyocytes of the border zone (BZ) region adjacent 
to the infarct in both patients with MI and experimental 
animal models.5,7 Whether activation of Runx1 in adult 
cardiomyocytes after MI is simply a marker of myocardial 
damage or actually plays a role in the progression of 
adverse cardiac remodeling is currently unknown.
We have now addressed this question by inducing 
MI in a mouse model in which Runx1 has been spe-
cifically excised in cardiomyocytes. We report that these 
mice were protected against adverse cardiac remodel-
ing after MI, with markedly preserved LV systolic func-
tion through improved SR-mediated calcium uptake. 
Reactivation of Runx1 after MI therefore plays a cru-
cial role in excitation-contraction coupling and adverse 
cardiac remodeling and represents a new therapeutic 
target with the potential to limit progression to heart 
failure among patients with MI.
METHODS
Detailed methods are provided in the online-only Data 
Supplement. The care and use of animals were in accordance 
with the UK Government Animals (Scientific Procedures) Act 
1986. All animal procedures were approved by the University 
of Glasgow Animal Welfare and Ethical Review Body and 
licensed by the Home Office, UK (project license no. 600/4503).
Coronary Artery Ligation
Mice 10 to 12 weeks of age (weight, 25–30 g) underwent 
thoracotomy and left anterior descending coronary artery 
ligation (permanent/temporary) using standard approaches.
Generation of Cardiomyocyte-Specific 
Runx1-Knockout Mice
Runx1fl/fl mice, described previously,8 were crossed with mice 
expressing tamoxifen-inducible Cre recombinase (MerCreMer) 
under the control of the cardiac-specific αMHC (α-myosin 
heavy chain)9 to produce the relevant test and control cohorts 
(online-only Data Supplement). Polymerase chain reaction 
(PCR) of genomic DNA, RNA isolation, cDNA synthesis, real-
time quantitative PCR analysis, and immunoblotting are 
detailed in the online-only Data Supplement.
Cardiac Phenotyping
Echocardiographic M-mode measurements were performed 
before and after left anterior descending coronary artery 
Clinical Perspective
What Is New?
• Our study provides new evidence that Runx1, a 
gene intensively studied in the cancer and blood 
research fields, has a critical role in cardiomyocytes 
after myocardial infarction.
• We provide conclusive evidence that increased 
Runx1 expression under pathological conditions 
leads to decreased cardiac contractile function.
• Experiments performed with a newly generated 
cardiomyocyte-specific Runx1-deficient mouse 
reveal that reducing Runx1 function preserves myo-
cardial contractility and prevents adverse cardiac 
remodeling after myocardial infarction.
What Are the Clinical Implications?
• Our mechanistic data robustly demonstrate that 
Runx1 modulates cardiac sarcoplasmic reticulum 
calcium uptake and contractile function.
• Reducing Runx1 function drives increased contrac-
tility after myocardial infarction, thereby preserv-
ing left ventricular systolic function and preventing 
adverse cardiac remodeling.
• Our study therefore identifies Runx1 as a new 
target holding major promise for limiting the pro-
gression to heart failure among patients with myo-
cardial infarction by preventing adverse cardiac 
remodeling.
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ligation and pressure-volume (PV) loop measurements 
recorded as a terminal procedure with the Scisense/Transonic 
small animal model PV system.
Histology
Quantification of regional areas and infarct size was per-
formed on Picrosirius Red/triphenyl tetrazolium chloride–
stained histological sections with Image J and Adobe 
Photoshop. Cardiomyocyte size was assessed by AlexaFluor-
conjugated wheat germ agglutinin (Invitrogen, UK) on 
adjacent sections. RNAscope with probes to specifically 
identify cardiomyocyte nuclei (pericentriolar material 1) and 
Runx1 was performed as detailed in the online-only Data 
Supplement. For each heart, positive (PPIB and POLR2A) and 
negative controls (bacterial dapB) were run (Figure I in the 
online-only Data Supplement).
Calcium Measurements
Cardiomyocytes were isolated as previously described,10 
loaded with a calcium-sensitive fluorophore (5.0 μmol/L 
Fura-4F AM, Invitrogen), and perfused during field stimula-
tion (1.0 Hz, 2.0-ms duration, stimulation voltage set to 1.5 
times the threshold). The Fura-4F fluorescence ratio (340/380-
nm excitation) was measured with a spinning wheel spectro-
photometer (Cairn Research Ltd; sampling rate of 5.0 kHz) 
to measure the cardiomyocyte intracellular calcium concen-
tration ([Ca2+]i). Cell-edge detection (IonOptix) was used to 
measure cell length. Data were analyzed offline as previously 
described.11 Particular experiments used pretreatment (30 
minutes) and perfusion with the protein kinase A (PKA) inhibi-
tor H89 (1 μmol/L; Tocris Biosciences, Bristol, UK) as previously 
described.12
Adenoviral Overexpression of Runx1  
In Vitro
Adenoviral vectors expressing either enhanced green fluo-
rescent protein or green fluorescent protein and Runx1 in 
a bicistronic configuration (Ad-Runx1) were prepared and 
titered (online-only Data Supplement). Cardiomyocytes iso-
lated from adult New Zealand white rabbits (3 kg) were cul-
tured and transduced at a multiplicity of infection of 100 for 
24 hours.
Statistics
Data were expressed as mean±SEM. Comparisons between 
MI and sham hearts were performed with the Student t 
test on raw data before normalization to percentage 
change. Comparisons between >2 groups were conducted 
on raw data with ANOVA. In cases when the 2 control 
groups were combined, statistics were performed on the 
pooled raw data of both control groups and compared 
with Runx1Δ/Δ mice with the Student t test. In experiments 
in which multiple isolated cardiomyocyte observations (n) 
were obtained from each heart (N), we have first ensured 
normality of data distribution and then determined the 
differences between control and experimental mice using 
linear mixed modeling (IBM SPSS Statistics, version 22) as 
previously published.13
RESULTS
Expression of Runx1 After MI
Although Runx1 expression has previously been shown 
to increase at 3 weeks after MI, it was unknown wheth-
er increased Runx1 expression occurred at a later time 
point after MI (eg, 8 weeks after MI). Furthermore, tem-
poral changes in regional Runx1 expression have not 
previously been investigated. Runx1 expression was 
therefore quantified in hearts taken from C57BL/6J 
mice with MI induced by permanent coronary artery 
ligation and compared with C57BL/6J mice that had 
a sham procedure but no coronary artery ligation. PV 
loop measurements confirmed that C57BL/6J mice with 
MI had reduced systolic (Figure IIA–IIC in the online-on-
ly Data Supplement) and diastolic (Figure IID and IIE in 
the online-only Data Supplement) function with a lower 
ejection fraction (Figure IIF–IIH in the online-only Data 
Supplement).
Runx1 mRNA and Protein Levels
The levels of Runx1 mRNA increased by 2.5-fold in whole 
hearts 4 weeks after MI relative to 4-week sham hearts 
(P<0.05; Figure II in the online-only Data Supplement). 
To determine the contribution of specific myocardial 
regions to the observed increase in Runx1 mRNA level, 
a separate cohort of sham and MI hearts was isolated, 
and tissue was isolated from 4 different regions (Figure 
IIJ in the online-only Data Supplement). Runx1 mRNA 
levels analyzed with the relative quantification method 
increased by 5.1-fold and 1.8-fold in the infarct and BZ 
regions of 4-week post-MI hearts relative to the respec-
tive right ventricular (RV) region (P<0.05; Figure IIK in the 
online-only Data Supplement). No detectable change 
was noted in the Runx1 mRNA levels in the LV region at 
4 weeks after MI, and no statistically significant regional 
differences were detected in the sham hearts (Figure IIK 
in the online-only Data Supplement).
The levels of Runx1 protein changed in line with lev-
els of Runx1 mRNA (Figure IIL and IIM in the online-
only Data Supplement). Runx1 protein levels increased 
by 6.4-fold and 13.0-fold in the BZ and infarct regions, 
respectively, relative to the LV region in 3-week post-MI 
hearts (P<0.05).
The pattern of Runx1 mRNA expression was similar 
in 8-week post-MI hearts, with an increase of 3.7-fold 
and 2.2-fold in the infarct and BZ regions, respectively, 
relative to the corresponding RV region (P<0.05; Fig-
ure III in the online-only Data Supplement). However, 
in contrast to 4-week post-MI hearts, the Runx1 mRNA 
levels were increased by 2.7-fold in the LV region rela-
tive to the RV region (P<0.05) at the 8-week time point 
(Figure III in the online-only Data Supplement).
All of the observed regional changes in Runx1 mRNA 
expression occurred in the absence of any such changes 
in the RV region of MI hearts relative to sham hearts.
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Expression of Runx1 in Cardiomyocytes 
After MI
We next delineated the spatial-temporal expression of 
Runx1 in cardiomyocytes from other cardiac cell types 
within different regions of the heart using RNAscope. 
Runx1 expression was found in 8% to 13% of cardio-
myocytes and 5% to 7% of noncardiomyocytes in the 
4 regions (RV, LV, and equivalent BZ and infarct zone) 
of sham hearts (Figure 1A–1C). Runx1 expression did 
not significantly differ from sham levels in the RV and 
LV regions at 1 and 14 days after MI (Figure 1A–1C). 
However, Runx1 expression significantly increased to 
43% and 44% of cardiomyocytes within the BZ and 
infarct regions, respectively, at 1 day after MI, a time 
when whole-heart contractile dysfunction was also first 
observed (Figure 1A and 1B and Figure IV in the online-
only Data Supplement). Furthermore, Runx1 expression 
significantly increased to 59% and 47% of cardiomyo-
cytes within the BZ and infarct regions, respectively, at 
Figure 1. Runx1 expression in wild-type (WT) C57BL/6 mice after myocardial infarction (MI).  
A, Typical images of regional heart sections with RNA in situ hybridization (using RNAscope). Regions examined were the right 
ventricle (RV), left ventricle (LV), border zone (BZ), and infarct (INF) at 1 day (middle; n=3) and 14 days (bottom; n=3) after MI 
and equivalent regions in sham hearts (top; n=5). Probes for Runx1 (pink) and pericentriolar material 1 (PCM-1; cardiomyocyte-
specific; brown) were used; colored punctate dots represent positive staining (arrows). Scale bar, 10 μm; magnified inset image, 
5 μm. B, Mean quantification of cardiomyocytes (PCM-1+) and (C) noncardiomyocytes (PCM-1−) with Runx1-positive staining as 
a percent of the total number of cardiomyocytes or noncardiomyocytes, respectively. *P<0.05, 1 day after MI vs. sham. #P<0.05, 
14 days after MI vs. sham, Student t test. D, Runx1 expression as measured by real-time quantitative polymerase chain reaction in 
cardiomyocytes isolated from whole sham (n=17) and 1-day (n=8), 7-day (n=6), and 14-day (n=3) post-MI hearts (ANOVA). Stock 
(C57BL/6J; n=4) mice were included to show that there was no detectable difference from sham hearts (ANOVA).
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14 days after MI (Figure  1A and 1B). With regard to 
other cardiac cell types, Runx1 expression significantly 
increased to 14% of noncardiomyocytes within the in-
farct region at 1 day after MI (Figure 1A and 1C) and 
increased further to 35% and 26% of noncardiomyo-
cytes within the BZ and infarct regions, respectively, at 
14 days after MI (Figure 1A and 1C). These data sup-
ported separate experiments that found an increased 
Runx1 level at 1 and 14 days after MI in cardiomyocytes 
isolated from whole hearts and separated from other 
cell types as measured with real-time quantitative PCR 
data even though these data did not provide spatial 
resolution (Figure 1D).
Direct Assessment of Runx1 Function  
in Cardiomyocytes
To directly determine the contribution of Runx1 in 
cardiomyocytes to reduced cardiac function, we gen-
erated cardiomyocyte-specific Runx1-deficient mice 
using Cre-LoxP–based gene targeting strategies (on-
line-only Data Supplement and Figure V in the online-
only Data Supplement).9 Three groups of mice were 
generated: Runx1Δ/Δ mice (αMHC-MerCreMer:Runx1fl/
fl), littermate Runx1fl/fl mice controlling for the inser-
tion of the LoxP sites,8 and Runx1wt/wt mice controlling 
for insertion of the tamoxifen-inducible Cre recombi-
nase (αMHC-MerCreMer:Runx1wt/wt).9 Cardiomyocyte-
specific excision of Runx1 was induced in adult mice 
by a single intraperitoneal injection of tamoxifen (40 
mg/kg). PCR of genomic DNA, real-time quantitative 
PCR, and Western blot analysis were performed on iso-
lated cardiomyocytes and confirmed successful deletion 
of the Runx1 gene after injection with tamoxifen (Fig-
ure V in the online-only Data Supplement).
In Vivo Echocardiographic Assessment of 
Runx1Δ/Δ Mice After MI
To establish whether LV systolic function was altered in 
Runx1Δ/Δ mice after MI, we used M-mode echocardiog-
raphy.
Cardiac Function
MI was surgically induced in Runx1Δ/Δ, Runx1fl/fl, and 
Runx1wt/wt mice 1 week after tamoxifen injection in 
all mice. Echocardiography was performed before MI 
and every 2 weeks after MI to assess cardiac contrac-
tile function (Figure 2A). As expected, cardiac systolic 
function (assessed by fractional shortening) decreased 
in both groups of control mice (Runx1fl/fl and Runx1wt/
wt) after MI (Figure 2B). In contrast, Runx1Δ/Δ mice dem-
onstrated a markedly preserved fractional shortening 
that was 158% of the control mice at 8 weeks after 
MI (39.5±0.7% versus 24.9±1.9%; P<0.05; Figure 2A 
and 2B). Runx1Δ/Δ mice undergoing a sham procedure 1 
week after tamoxifen injection demonstrated no change 
in fractional shortening over the equivalent 8-week 
time course and were not significantly different from 
the Runx1Δ/Δ MI mice until the 8-week time point (Fig-
ure 2B). The improved fractional shortening in Runx1Δ/Δ 
mice after MI was the culmination of substantially im-
proved cardiac contraction, as evidenced by the smaller 
LV internal diameter measured at systole (Figure 2A and 
2C), which was 77% of the 2 control groups after MI 
(2.5±0.2 versus 3.3±0.1 mm; P<0.05). Runx1Δ/Δ mice 
undergoing a sham procedure after tamoxifen adminis-
tration demonstrated no change in LV internal diameter 
measured at systole over the equivalent 8-week time 
course. The LV internal diameter measured at diastole 
within the BZ region indicated that the hearts of both 
control and Runx1Δ/Δ mice after MI dilated at this level 
of the myocardium, albeit to a lesser degree in Runx1Δ/Δ 
mice (Figure 2D).
Cardiac Structure
As expected, LV posterior wall thickness during systole 
measured at the level of the BZ of control mice (Runx1fl/
fl and Runx1wt/wt) thinned after the 2-week post-MI time 
point as a result of the cardiac remodeling process (Fig-
ure 2E). In contrast, Runx1Δ/Δ mice displayed preserved 
wall thickness that was 164% of control mice (Runx1fl/
fl and Runx1wt/wt) at 8 weeks after MI (2.07±0.14 ver-
sus 1.27±0.06 mm; P<0.05; Figure 2E). Runx1Δ/Δ mice 
undergoing a sham procedure after MI demonstrated 
no change in LV posterior wall thickness during systole 
over the equivalent 8-week time course. The wall thick-
ness data were confirmed at diastole 8 weeks after MI 
(Figure 2F).
These data were confirmed in a separate blinded 
study (Figure VIA–VIE in the online-only Data Supple-
ment) in which the operator was blinded to the animals 
undergoing surgery, echocardiography, and analysis 
before MI and at 2 weeks after MI and at earlier time 
points at and before 1 week after MI (Figure VII in the 
online-only Data Supplement).
In Vivo Ventricular Luminal Volumes  
and Ejection Fraction in Runx1Δ/Δ Mice  
2 Weeks After MI
LV ventricular luminal volume of the Runx1Δ/Δ and con-
trol mice was assessed in vivo at 2 weeks after MI with 
PV loops (Figure 2G). The end-diastolic volume in the 
Runx1Δ/Δ mice was reduced to 82% of that in control 
mice (Runx1fl/fl and Runx1wt/wt), indicating a reduction 
in LV dilation (36.3±3.00 versus 44.5±2.47 μL; P<0.05; 
Figure 2G and 2H). The end-systolic volume in Runx1Δ/Δ 
mice was reduced to 54% of the control mice, indi-
cating a greater level of emptying of LV blood volume 
(12.9±2.98 versus 23.7±2.51 μL; P<0.05; Figure 2G and 
2I). This leftward shift in the PV loop in the Runx1Δ/Δ 
 by guest on January 16, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
McCarroll et al
January 2, 2018 Circulation. 2018;137:57–70. DOI: 10.1161/CIRCULATIONAHA.117.02891162
mice resulted in an ejection fraction that was 138% 
of the control mice (66.3±5.69% versus 48.0±3.18%; 
P<0.05; Figure 2G and 2J).
Histological Assessment of Runx1Δ/Δ  
Mice 8 Weeks After MI
Heart Structure
We next investigated whether an altered whole-heart 
structure contributed to the preserved cardiac perfor-
mance of Runx1Δ/Δ mice after MI. Analysis of the differ-
ent regions of the heart (Figure 3A) with Picrosirius Red 
staining of serial sections of hearts from Runx1Δ/Δ mice 
8 weeks after MI showed that the mean 2-dimensional 
whole-heart area (RV+septum+LV+infarct) was 112% of 
control mice (Runx1fl/fl and Runx1wt/wt) after MI (37.4±1.4 
versus 33.5±0.6 mm2; P<0.05; Figure 3B). This increase 
in heart area was associated with the LV free wall (Fig-
ure 3A, dotted area), which in Runx1Δ/Δ mice after MI 
was 127% of control mice after MI (11.0±0.8 versus 
8.7±0.4 mm2; P<0.05; Figure 3C). No change was de-
tected in the RV wall area in Runx1Δ/Δ mice after MI (Fig-
ure 3D); therefore, further investigation focused on the 
structure of the LV.
LV wall thickness (measured at the level of the BZ; 
Figure 3A, arrows) in Runx1Δ/Δ mice after MI was 127% 
Figure 2. Cardiac function in Runx1Δ/Δ mice.  
A, Echocardiography (scale: x=0.1 s; y=2 mm). B, The 8-week echocardiographic data for fractional shortening (FS) and (C) left 
ventricular (LV) internal diameter (LVID) at systole (LVIDs), (D) LVID at diastole (LVIDd), (E) LV posterior wall thickness at systole 
(LVPWs), and (F) LVPW thickness at diastole (LVPWd). (Runx1fl/fl myocardial infarction [MI] and Runx1wt/wt MI combined [n=11], 
Runx1Δ/Δ MI [n=9], and Runx1Δ/Δ sham [n=5]; ANOVA.) #P<0.05, Runx1Δ/Δ MI mice vs. Runx1Δ/Δ sham mice. *P<0.05, Runx1Δ/Δ 
MI mice vs. control Runx1fl/fl MI and Runx1wt/wt MI mice combined. G, Pressure-volume (PV) loops of Runx1wt/wt and Runx1Δ/Δ 2 
weeks after MI. H, Mean PV data 2 weeks after MI, end-diastolic volume (EDV), (I) end-systolic volume (ESV), and (J) ejection 
fraction (EF; Runx1fl/fl MI and Runx1wt/wt MI combined [n=11], Runx1Δ/Δ MI [n=8]). *P<0.05, Student t test.
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Figure 3. Runx1Δ/Δ mice cardiac structure 8 weeks after myocardial infarction (MI).  
A, Picrosirius Red–stained hearts. Scale, 1 mm. BZ indicates border zone; INF, infarct; LV, left ventricle; RV, right ventricle; and 
SEP, septum. Mean (B) area of whole heart (all regions), (C) LV, (D) RV, and (E) LV wall thickness at BZ region; (F) septum wall 
thickness at BZ region level; (G) ratio of heart weight to body weight; (H) infarct thickness; (I) LV fibrosis; and (J) infarct size 
(Runx1fl/fl MI and Runx1wt/wt MI combined [n=12], Runx1Δ/Δ MI [n=5]). *P<0.05, Student t test. K, Wheat germ agglutinin (WGA) 
staining of LV cardiomyocytes (longitudinal) of Runx1fl/fl MI (top) and Runx1Δ/Δ (bottom) after MI (scale bar, 25 mm). L, Mean 
LV cardiomyocyte length (Runx1Δ/Δ sham [n=55 cardiomyocytes, n=3 hearts], Runx1fl/fl MI [n=122 cardiomyocytes, n=6 hearts], 
Runx1wt/wt MI [n=109 cardiomyocytes, n=6 hearts], Runx1Δ/Δ MI [n=102 cardiomyocytes, n=6 hearts]). *P<0.05, linear mixed 
modeling. M, Mean SEP cardiomyocyte length (Runx1Δ/Δ sham [n=29 cardiomyocytes, n=3 hearts], Runx1fl/fl MI [n=82 cardio-
myocytes, n=6 hearts], Runx1wt/wt MI [n=84 cardiomyocytes, n=6 hearts], Runx1Δ/Δ MI [n=64 cardiomyocytes, n=6 hearts]). N, 
WGA staining of LV cardiomyocytes (transverse) of Runx1wt/wt MI (left) and Runx1Δ/Δ MI (right; scale bar, 25 mm). O, Mean LV 
cardiomyocyte diameter (Runx1Δ/Δ sham [n=449 cardiomyocytes, n=3 hearts], Runx1fl/fl MI [n=811 cardiomyocytes, n=6 hearts], 
Runx1wt/wt MI [n=897 cardiomyocytes, n=6 hearts], Runx1Δ/Δ MI [n=878 cardiomyocytes, n=6 hearts]). P, Mean LV cardiomyo-
cyte cross-sectional area (Runx1Δ/Δ sham [n=403 cardiomyocytes, n=3 hearts], Runx1fl/fl MI [n=714 cardiomyocytes, n=6 hearts], 
Runx1wt/wt MI [n=785 cardiomyocytes, n=6 hearts], Runx1Δ/Δ MI [n=699 cardiomyocytes, n=6 hearts]). Q, Mean SEP cardiomyo-
cyte diameter (Runx1Δ/Δ sham [n=238 cardiomyocytes, n=3 hearts], Runx1fl/fl MI [n=465 cardiomyocytes, n=6 hearts], Runx1wt/wt 
MI [n=454 cardiomyocytes, n=6 hearts], Runx1Δ/Δ MI [n=452 cardiomyocytes, n=6 hearts]). *P<0.05, linear mixed modeling.
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of control mice after MI (2.07±0.2 versus 1.63±0.1 
mm; P<0.05; Figure 3E), a finding that supported the 
echocardiographic data (Figure  2E). No change was 
detected in the septal wall thickness in Runx1Δ/Δ mice 
after MI (Figure 3F) or overall heart weight (Figure 3G). 
Infarct thickness and fibrosis (Figure 3H and 3I) were 
not different in Runx1Δ/Δ mice after MI versus control 
mice after MI. Furthermore, infarct size (32.3±1.5% 
versus 32.7±3.1% versus 31.9±5% of LV; Runx1Δ/Δ 
[N=5] versus Runx1wt/wt [N=7] versus Runx1fl/fl [N=5]; 
P>0.05; Figure 3J) at 8 weeks after MI (and the earlier 
time point of 24 hours after MI; Figure VIIIA and VIIIB 
in the online-only Data Supplement) was not differ-
ent in Runx1Δ/Δ versus control mice and therefore did 
not explain the preserved LV function observed in vivo 
(Figure 2B).
Cardiomyocyte Size
To investigate why LV free wall thickness was preserved 
in Runx1Δ/Δ mice 8 weeks after MI relative to the wall 
thinning observed in control mice after MI (Figure 2E and 
2F), the cardiomyocyte size in Runx1Δ/Δ mice 8 weeks 
after MI was determined with wheat germ agglutinin 
staining. As expected, LV cardiomyocytes from control 
Runx1fl/fl and Runx1wt/wt mice 8 weeks after MI exhib-
ited significant cell lengthening to 121% and 118% of 
Runx1Δ/Δ sham mice (111.7±3.8 versus 108.8±3.7 ver-
sus 92.53±1.04 μm; P<0.05; Figure 3K and 3L). How-
ever, cardiomyocyte elongation was absent in Runx1Δ/Δ 
mice at 8 weeks after MI (Figure 3K and 3L). An equiva-
lent absence of cardiomyocyte lengthening was also 
observed in septal cardiomyocytes (Figure 3M). LV car-
diomyocytes from control Runx1fl/fl and Runx1wt/wt mice 
8 weeks after MI exhibited a significant decrease in 
cell diameter to 86% and 85% of Runx1Δ/Δ sham mice 
(15.91±0.83 versus 15.88±0.75 versus 18.86±0.37 
μm; P<0.05; Figure 3N and 3O). However, cardiomyo-
cyte cell diameter did not decrease in Runx1Δ/Δ mice 8 
weeks after MI (Figure  3O). LV cardiomyocytes from 
control Runx1fl/fl and Runx1wt/wt mice 8 weeks after MI 
exhibited a significant decrease in cardiomyocyte cross-
sectional area to 79% and 76% of Runx1Δ/Δ sham mice 
(350.6±23.9 versus 338.2±22.6 versus 440.0±11.5 μm; 
P<0.05; Figure  3N and 3P). However, cardiomyocyte 
cell cross-sectional area did not decrease in Runx1Δ/Δ 
mice 8 weeks after MI (Figure 3P). No change in septal 
cardiomyocyte diameter was observed at 8 weeks after 
MI in any group (Figure 3Q).
Calcium Transients in Runx1Δ/Δ Mice 2 
Weeks After MI
Although increased fractional shortening paralleled in-
creased wall thickness in Runx1Δ/Δ mice at 8 weeks after 
MI (Figure  2B and 2E), we noted that wall thickness 
was not significantly different between the 3 groups at 
2 weeks after MI. However, Runx1Δ/Δ mice still exhib-
ited greater fractional shortening at this time point than 
was observed for the 2 control groups. To investigate 
this dichotomy, we isolated cardiomyocytes from hearts 
at 2 weeks after MI to characterize calcium handling. 
This was achieved by measuring the [Ca2+]i, focusing on 
electrically induced SR-mediated calcium release (cal-
cium transients) into the cytosol, which predominately 
determines the force of contraction.
Cardiomyocytes isolated at 2 weeks after MI were 
stimulated at 1.0 Hz to elicit calcium transients and cell 
shortening (Figure 4A–4C). The calcium transient peak 
(systolic [Ca2+]i) in Runx1
Δ/Δ mice was 117% and 122% 
of control (Runx1fl/fl and Runx1wt/wt) mice (582.8±36.1 
versus 497.4±31.3 versus 477.0±24.5 nmol/L [Ca2+]i; 
P<0.05; Figure  4B and 4D). The calcium transient 
minimum (diastolic [Ca2+]i) in Runx1
Δ/Δ mice was 92% 
and 89% of control (Runx1fl/fl and Runx1wt/wt) mice 
(137.8±4.5 versus 149.8±6.3 versus 155.1±6.8 nmol/L 
[Ca2+]i; P<0.05; Figure 4B and 4E). The changes in peak 
and minimum [Ca2+]i of Runx1
Δ/Δ mice resulted in a cal-
cium transient amplitude that was 128% and 138% 
of control (Runx1fl/fl and Runx1wt/wt) mice (445.0±34.3 
versus 347.5±29.0 versus 321.9±20.7nmol/L [Ca2+]i; 
P<0.05; Figure  4B and 4F). Furthermore, the time 
constant of calcium transient decay in the Runx1Δ/Δ 
mice was 65% and 55% of control (Runx1fl/fl and 
Runx1wt/wt) mice (0.074±0.007 versus 0.114±0.018 
versus 0.134±0.020 s; P<0.05; Figure 4B and 4G), sug-
gesting an increased rate of removal of calcium from 
the cytosol.
The increased calcium transient amplitude in 
Runx1Δ/Δ mice after MI occurred in the absence of any 
significant changes in calcium entry or action potential 
duration (as measured indirectly with the QT interval 
on the ECG or directly with voltage measurements on 
isolated cardiomyocytes at 2 weeks after MI; Figure IX 
in the online-only Data Supplement).
Caffeine-Induced Calcium Transients and Cell 
Shortening
We hypothesized that the lowered time constant of 
decay detected in the Runx1Δ/Δ mice 2 weeks after MI 
might reflect either increased SR calcium uptake via sar-
co/endoplasmic reticulum Ca2+-ATPase (SERCA) or ex-
trusion from the cell via the sodium-calcium exchanger. 
To address this issue, we applied a rapid bolus of 10 
mmol/L caffeine at the end of the protocol to release 
all of the calcium from the SR into the cytosol. This ap-
proach enabled assessment of SR calcium content.
The SR calcium content of the Runx1Δ/Δ mice was 
135% and 118% of the control Runx1fl/fl and Runx1wt/
wt mice, respectively (842.8±47.2 versus 624.3±42.2 
versus 712.6±40.0 nmol/L [Ca2+]i; P<0.05; Figure 4H). 
SERCA-mediated calcium uptake is bypassed during ap-
plication of 10 mmol/L caffeine, and cytosolic calcium 
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removal occurs predominately via the sodium-calcium 
exchanger. The activity of the sodium-calcium exchang-
er, as assessed by the time constant of caffeine-induced 
calcium transient decay, was not different between the 
3 groups (Figure 4I).
The increased SR calcium content observed in 
Runx1Δ/Δ mice might reflect enhanced SERCA activity 
(KSERCA). Therefore, we measured the rate constant of 
decay of the caffeine-induced calcium transient (which 
includes sarcolemmal efflux but not SR calcium uptake) 
and subtracted this value from that of the electrically 
stimulated calcium transient (which includes both SR 
calcium uptake and sarcolemmal efflux).14,15 The KSERCA 
of the Runx1Δ/Δ mice was 148% and 160% of control 
Runx1fl/fl and Runx1wt/wt mice (14.4±1.4 versus 9.7±1.8 
versus 9.0±1.2 s−1; P<0.05; Figure  4J). To corrobo-
rate that the increased calcium transient amplitude of 
Runx1Δ/Δ mice resulted in increased cell shortening, we 
performed edge-detection shortening measurements 
(Figure  4C). Cardiomyocyte shortening in Runx1Δ/Δ 
mice 2 weeks after MI was 156% and 203% of the 
control Runx1fl/fl and Runx1wt/wt mice (7.5±0.9% versus 
4.8±0.6% versus 3.7±0.4% of diastolic length; P<0.05; 
Figure 4C and 4K).
Effect of Overexpressing Runx1 on Calcium 
Transient Amplitude and SR Calcium Content  
in Normal Cardiomyocytes
To further support the novel link between Runx1 and cal-
cium handling in isolated cardiomyocytes, we performed 
a gain-of-function study by overexpressing Runx1 via ad-
enoviral-mediated gene transfer (Ad-Runx1) in isolated 
adult cardiomyocytes from normal hearts. The calcium 
Figure 4. Excitation-contraction coupling in Runx1Δ/Δ mice 2 weeks after myocardial infarction (MI). 
A, Protocol, (B) typical calcium (Ca2+) transients, and (C) cell shortening. Mean Ca2+ transient: (D) peak, (E) minimum, and 
(F) amplitude (Runx1fl/fl MI [n=25 cardiomyocytes, n=3 hearts], Runx1wt/wt MI [n=28 cardiomyocytes, n=4 hearts], Runx1Δ/Δ MI 
[n=28 cardiomyocytes, n=3 hearts]). *P<0.05, Runx1Δ/Δ MI vs. Runx1fl/fl MI and Runx1wt/wt MI combined, linear mixed modeling. 
G, Mean time constant of Ca2+ transient decay. H, Mean caffeine-induced Ca2+ transient amplitude. I, Mean time constant of 
decay for caffeine-induced Ca2+ transient amplitude. J, Mean sarcoendoplasmic reticulum calcium transport ATPase (SERCA) 
activity. K, Mean fractional shortening (Runx1fl/fl MI [n=27 cardiomyocytes, n=3 hearts], Runx1wt/wt MI [n=27 cardiomyocytes, 
n=4 hearts], Runx1Δ/Δ MI [n=23 cardiomyocytes, n=3 hearts]). L, Ca2+ transients from cardiomyocytes transduced with en-
hanced green fluorescent protein (Ad-GFP) or Ad-Runx1. M, Mean Ca2+ transient peak; Ad-GFP (n=16 cardiomyocytes, n=6 
hearts) and Ad-Runx1 (n=22 cardiomyocytes, n=6 hearts). *P<0.05, linear mixed modeling. N, Caffeine-induced Ca2+ transient 
amplitude, Ad-GFP (n=13 cardiomyocytes, n=6 hearts), and Ad-Runx1 (n=19 cardiomyocytes, n=6 hearts). *P<0.05, linear 
mixed modeling.
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transient amplitude in Ad-Runx1–transduced cardio-
myocytes was 53% of cardiomyocytes transduced with 
the control adenoviral vector expressing green fluores-
cent protein (70.5±8.3 versus 133.4±30.7 nmol/L [Ca2+]i; 
P<0.05; Figure 4L and 4M). SR calcium content in cardio-
myocytes overexpressing Runx1 was 60% of the control 
cardiomyocytes (388.8±60.3 versus 651.8±84.4 nmol/L 
[Ca2+]i; P<0.05; Figure 4N).
Expression of Calcium Handling Proteins 
in Runx1Δ/Δ Mice 2 Weeks After MI
To investigate the mechanism by which SERCA activity 
is increased, we quantified the expression and phos-
phorylation levels of key calcium handling proteins in-
volved in the control of SERCA-mediated calcium up-
take in isolated cardiomyocytes 2 weeks after MI.
Levels of phospholamban, an inhibitory protein that 
regulates SERCA activity, were not significantly altered 
in the Runx1Δ/Δ mice (Figure 5A and 5B). In contrast, 
phosphorylation of phospholamban (which relieves 
SERCA inhibition and improves cardiac contractility) 
at the PKA-target residue Ser16 was 331% of control 
mice (Runx1wt/wt and Runx1fl/fl; 331.2±94.5% versus 
100±35.6% change; P<0.05; Figure 5A and 5C).
Decreased levels of protein kinase C indirectly en-
able enhanced phosphorylation of phospholamban and 
increase cardiac contractility16; however, no between-
group differences were detected in the levels of protein 
kinase C (Figure 5D and 5E). Phosphorylation of phos-
pholamban at the Ca2+/calmodulin-dependent protein 
kinase II target residue threonine-17 in Runx1Δ/Δ mice 
was 175% of control mice (Runx1wt/wt and Runx1fl/fl; 
175.0±22.9% versus 100±8.2% change; P<0.05; Fig-
ure 5D and 5F). A possible regulator of phosphorylation 
of phospholamban is protein phosphatase 1, which 
dephosphorylates phospholamban.16 We found that 
expression of protein phosphatase 1 in Runx1Δ/Δ mice 
was decreased to 28% of control mice (Runx1wt/wt and 
Runx1fl/fl) after MI (27.6±19.4% versus 100±21.3% 
change; P<0.05; Figure 5G and 5H).
To confirm that the increased SERCA activity, SR 
calcium content, and calcium transient amplitude ob-
served in Runx1Δ/Δ mice 2 weeks after MI (Figure  4) 
were PKA-mediated, we investigated the effect of the 
PKA inhibitor (H89) on calcium handling. The addition 
of H89 completely blocked enhancement of all 3 pa-
rameters in the Runx1Δ/Δ mice relative to the control 
Runx1wt/wt and Runx1fl/fl mice (Figure 5I–5K).
Cardiac Contractility in Runx1Δ/Δ Mice 
After Ischemia With Reperfusion
Reperfusion of a blocked coronary artery limits cell 
death after MI; this effect can be achieved clinically via 
percutaneous coronary intervention. We therefore test-
ed whether Runx1Δ/Δ mice also maintain a preserved LV 
contractile function in an additional clinically relevant 
model of ischemia with reperfusion.
The left anterior descending coronary artery was 
temporarily ligated in vivo for 45 minutes followed 
by reperfusion, and the Runx1Δ/Δ mice recovered for 8 
weeks. Fractional shortening was assessed with echo-
cardiography before MI and weekly after the induction 
of MI with reperfusion. As expected, fractional shorten-
ing decreased in control Runx1fl/fl mice after reperfusion 
(Figure 6A and 6B). In contrast, Runx1Δ/Δ mice demon-
strated markedly preserved fractional shortening, which 
was 154% of control Runx1fl/fl mice at 8 weeks after 
reperfusion (42.7±1.5% versus 27.7±2.13%; P<0.05; 
Figure 6A and 6B). As with the animal model of per-
manent coronary artery ligation, infarct size at 8 weeks 
after reperfusion (and the earlier time point of 24 hours 
after reperfusion) was not different in Runx1Δ/Δ versus 
control mice (Figure 6C and Figure VIIIC and VIIID in the 
online-only Data Supplement).
DISCUSSION
Runx1 has been most intensively studied in the hema-
topoietic system because its function is frequently cor-
rupted in different subtypes of leukemia. Although it is 
known to have a role in lineage differentiation and tis-
sue function in a range of other systems, there is almost 
no information relating to its role in adult cardiomyo-
cytes other than the observation that it can be reactivat-
ed after myocardial insult.5,7 Our novel study addressed 
a vital question: Is increased expression of RUNX1 after 
MI merely a marker of ischemic damage, or does it play 
a functional role in adult cardiomyocytes after MI? We 
provide new evidence that Runx1 has an important role 
in cardiomyocytes after MI. Reducing Runx1 function 
preserved cardiac contractility and prevented adverse 
cardiac remodeling, which suggests that targeting the 
actions of this gene could have important implications 
for patient survival after MI. This research transcends 
discipline boundaries because it not only widens the im-
portance of Runx1 to other fields of medicine but also 
describes a novel function for this gene.
Our results provide the first detailed quantification of 
regional Runx1 expression in mouse heart tissue after 
MI. At 4 weeks after MI, Runx1 mRNA was increased 
within the BZ myocardium and infarct region, which 
was sustained until at least 8 weeks after MI, at which 
time Runx1 expression also increased within the remote 
LV myocardium. This is important given that changes in 
Runx1 expression at the mRNA and protein levels are 
not restricted to rodent MI models but also occur in 
patients with MI.5,7 In separate experiments, we were 
able to demonstrate that Runx1 expression is increased 
within the BZ and infarct region after MI within the 
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contractile elements of the heart—that is, the cardio-
myocytes—as early as 1 to 14 days after MI (Figure 1).
To determine the specific contribution of Runx1 in 
cardiomyocytes to reduced cardiac contractility, we 
generated a new tamoxifen-inducible cardiomyocyte-
specific Runx1-deficient mouse with the hypothesis 
that these mice would demonstrate improved cardiac 
function. Induction of MI in control transgenic mice 
led to the expected LV wall thinning, cardiac dilation, 
and reduced contractility 8 weeks after MI. However, all 
of these adverse cardiac remodeling parameters were 
absent or reduced in Runx1Δ/Δ mice at this time point. 
One possible explanation for the observed preservation 
of systolic function could have been a reduction in the 
infarct size of Runx1Δ/Δ mice given that infarct size cor-
relates with systolic function.17 However, Runx1Δ/Δ mice 
exhibited preservation of geometric shape and contrac-
tility after MI, with no difference in infarct size (at both 
early and late time points) or fibrosis compared with 
control mice.
Figure 5. Phospholamban (PLB) regulation in isolated cardiomyocytes from Runx1Δ/Δ mice 2 weeks after myocardial 
infarction (MI).  
A, Western blot of PLB, phosphorylation of PLB at serine-16 [P-PLB (Ser16)], and pan-actin loading control. Percentage change 
in protein for (B) PLB and (C) P-PLB (Ser16/total PLB; Runx1Δ/Δ MI [n=5 hearts] vs. Runx1wt/wt and Runx1fl/fl MI [n=5 hearts]). 
*P<0.05, Student t test. D, Western blot of protein kinase C (PKC), PLB, and PLB phosphorylation at threonine-17 [P-PLB 
(Thr17)]. Percentage change in protein for (E) PKC and (F) P-PLB (Thr17/total PLB; Runx1Δ/Δ MI [n=5 hearts] vs. Runx1wt/wt MI 
and Runx1fl/fl MI [n=9 hearts]). *P<0.05, Student t test. G, Western blot of protein phosphatase 1 (PP1). H, Percentage change 
in PP1 (Runx1Δ/Δ MI [n=5 hearts] vs. Runx1wt/wt MI and Runx1fl/fl MI [n=9 hearts]). I through K, Mean sarcoendoplasmic reticu-
lum calcium transport ATPase (SERCA) activity, caffeine-induced calcium transient amplitude, and calcium transient amplitude 
data from Figure 4 compared with mean data obtained from 2-week post-MI isolated cardiomyocytes with H89 (hatched 
white column, Runx1wt/wt MI and Runx1fl/fl MI+H89 [n=16 cardiomyocytes, 3 hearts]; hatched red column, Runx1Δ/Δ MI+H89 
[n=15 cardiomyocytes, 3 hearts]). *P<0.05, Student t test.
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To establish the mechanism underlying these nota-
ble findings, we first investigated cardiomyocyte size. 
Control mice demonstrated the expected cardiomyo-
cyte lengthening and thinning (eccentric hypertrophy) 
at 8 weeks after MI.1 However, these changes were 
absent in Runx1Δ/Δ mice. Such protection against ec-
centric hypertrophy at 8 weeks after MI seems highly 
likely to have afforded Runx1Δ/Δ mice protection from 
ventricular dilation and thinning, ultimately leading to 
preserved contractility. Nevertheless, at 2 weeks after 
MI, the wall thickness in Runx1Δ/Δ mice was comparable 
to that of control mice (because wall thinning in control 
mice had not yet begun), but contractile function was 
still dramatically improved. This finding indicated that 
prevention of wall thinning and dilation could not fully 
explain the preserved contractile function observed at 2 
weeks after MI.
The above dichotomy led us to investigate calcium 
handling in cardiomyocytes isolated from Runx1Δ/Δ 
mice 2 weeks after MI, in particular electrically stimu-
lated calcium release (the calcium transient) from the 
intracardiomyocyte calcium store (the SR) and sub-
sequent cell shortening. Patients and animal models 
with MI typically exhibit calcium transients with lower 
amplitude and a slower rate of decline than control/
healthy cardiomyocytes, an observation largely attrib-
uted to reduced SR-mediated calcium uptake via SER-
CA.15 Runx1Δ/Δ mice exhibited increased calcium tran-
sient amplitude and reduced time constant of decline 
after MI compared with control mice after MI, result-
ing in an increase in cell shortening. The accompanying 
higher SR calcium content observed in Runx1Δ/Δ mice 
after MI can explain the enhanced calcium transient 
amplitude18 because equalizing the SR calcium content 
with H89 resulted in a calcium transient equivalent to 
that of control.
Analysis of the caffeine-induced calcium transient 
found no detectable change in sodium-calcium ex-
changer activity in Runx1Δ/Δ mice after MI compared 
with control mice after MI. However, enhanced SR-me-
diated calcium uptake via SERCA was observed in the 
Runx1Δ/Δ mice. SERCA activity is a major determinant 
of the SR calcium content. Furthermore, this pump is 
regulated predominately by the inhibitory protein phos-
pholamban. Although expression of phospholamban 
was not altered in Runx1Δ/Δ mice after MI, we explored 
some of the proteins that regulate phospholamban ac-
tivity.16
Phospholamban-mediated inhibition of SERCA is 
balanced by phosphorylation by PKA and Ca2+/calmod-
ulin-dependent protein kinase II (which relieves SERCA 
inhibition) and dephosphorylation by protein phospha-
tase 1 (which returns phospholamban to its inhibitory 
state16). We found that ventricular cardiomyocytes from 
Runx1Δ/Δ mice exhibited increased PKA-mediated phos-
phorylation of phospholamban, possibly as a result of 
reduced levels of protein phosphatase 1. These mecha-
nistic data suggest that phospholamban phosphoryla-
tion stimulates SERCA activity in Runx1Δ/Δ mice after MI 
and leads to an increased SR calcium content, which 
in turn increases electrically induced SR-mediated cal-
cium release and doubles cardiomyocyte contraction. 
Our proposed mechanism was supported by complete 
blockage of the enhanced calcium transient in cardio-
myocytes from Runx1Δ/Δ mice 2 weeks after MI by inhi-
bition of PKA. The enhanced rate of removal of calcium 
from the cytosol after increased SERCA activity is suffi-
cient to reduce the end-diastolic [Ca2+]i, which not only 
improves whole-heart relaxation but also may limit the 
stimulation of hypertrophic factors.1
Previous studies strongly support our proposed 
mechanism that the effect of Runx1 on SR function is a 
major contributor to the beneficial effects observed in 
Runx1Δ/Δ mice after MI. Decreased SR function has been 
demonstrated among patients with heart failure,15 and 
enhanced SR-mediated calcium cycling markedly pre-
served contractility, reduced adverse cardiac remodel-
ing, and delayed progression to heart failure at lev-
els not dissimilar from those observed in the present 
study.16,19
The key findings of our study will likely initiate fur-
ther research into the beneficial effects of decreasing 
Runx1 expression in alternative animal models of car-
diac disease. As a testament to this goal, we found 
Figure 6. Runx1Δ/Δ mice after  
ischemia with reperfusion (I/R).  
A, Echocardiographic images (scale: 
x=0.1 s; y=2 mm). B, Mean echo-
cardiographic fractional shortening 
(FS) data of Runx1fl/fl I/R (n=9) and 
Runx1Δ/Δ I/R (n=8). *P<0.05, Student 
t test. C, Mean infarct size (Runx1fl/
fl I/R [n=9] and Runx1Δ/Δ I/R [n=7]). 
Student t test. LV indicates left 
ventricular.
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that Runx1Δ/Δ mice are protected from adverse cardi-
ac remodeling in a separate clinically relevant surgical 
model. In this model, the blocked coronary artery was 
subsequently unblocked after a period of ischemia, as 
would be the case for patients undergoing percutane-
ous coronary intervention. These additional data fur-
ther support our study and the translational potential 
of this new target.
Although our strategy did not result in inactivation 
of the Runx1 gene in all cardiomyocytes, we postulate 
that cardiac function improves when only a subset of 
cardiomyocytes benefit from better Ca2+ handling af-
ter inactivation of Runx1. Because it is more feasible in 
a clinical setting to suppress genes in a subset of car-
diomyocytes rather than in all cells, we think Runx1 or 
targets showing a similar potency are particularly at-
tractive for therapeutic interventions.
Conclusions
We have demonstrated for the first time that Runx1 
modulates cardiac SR calcium uptake and contractile 
function. Reducing Runx1 function drives increased 
contractility after MI, thereby preserving LV systolic 
function and preventing adverse cardiac remodeling. 
Clinical studies clearly demonstrate that preserving car-
diac contractility and protecting against adverse cardiac 
remodeling are key factors in limiting the progression 
from MI to heart failure.2 Identification of a new ther-
apeutic target that achieves this objective is urgently 
required. To this end, we envisage that Runx1 will be 
exploited in future basic and translational studies to 
limit the progression of patients with MI to heart fail-
ure, thereby improving survival rates and quality of life.
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SUPPLEMENTAL MATERIAL 
  
2 
 
Requests by researchers to access the data, analytic methods, and study materials for the 
purposes of reproducing the results or replicating procedures can be made to the 
corresponding author who manages the information. 
Coronary artery ligation 
Mice aged 10–12 wk (25–30 g) were anesthetized by inhalation of 4% isofluorane gas 
(Isoflo, Abbott Laboratories, USA) delivered in O2 at 1.5 L/min. Animals were given 
preoperative analgesia of 5 mg/kg carprofen (Rimadyl, Pfizer Animal Health, U.) and 0.1 
mg/kg buprenorphine (Vetergesic, Reckitt Benckiser Healthcare Ltd, UK) i.p. delivered in 0.4 
mL of sterile saline. Mice were endotracheally intubated and maintained with artificial 
ventilation at 120 breaths/min with a tidal volume of 120 µL on 1% isofluorane in 0.5 L/min 
O2. Mice were positioned in a left lateral oblique position. The skin was incised perpendicular 
to the sternum in parallel with the ribs 5 mm proximal to the xyphoid process. Underlying 
muscles were carefully retracted to expose the fifth intercostal space beneath. The 
intercostal muscle was cut using an electrocautery pen and the ribs retracted to expose the 
heart. The pericardial sac was opened and removed to provide access to the left anterior 
descending (LAD) coronary artery which was then ligated with 0.3 metric nylon (W2829 
Ethilon, Johnson & Johnson, UK) 1.5 mm distal to the left atrial appendage. Three sutures 
were evenly pre-placed along the ribs using 0.7 metric non-absorbable prolene (W8711, 
Johnson & Johnson, UK). The lungs were reinflated until the pre-placed sutures were tied. 
The thoracic muscles were returned to their original position and skin closed with 0.7 metric 
absorbable vicryl (W9575, Johnson & Johnson, UK). Animals that underwent the sham 
procedure had a thoracotomy without LAD ligation. Temporary LAD ligation (I/R model) was 
achieved by using a piece of polyethylene tubing (PE-10; outer diameter 0.61 mm) against 
which the coronary artery was tied temporarily (45 min) and then subsequently released by 
removal of the tubing. Post-operatively, animals were given buprenorphine orally for 3 days. 
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RNA isolation, cDNA synthesis and real-time qPCR analysis 
Total RNA was extracted from heart tissue using the miRNeasy Mini Kit (Qiagen, UK) with 
DNase I treatment (Qiagen, UK). 1 µg of RNA was then reverse transcribed to cDNA with 
Omniscript reverse transcriptase, dNTPs, RNase inhibitors and oligo dT primers (Omniscipt 
Reverse Transcription kit, Qiagen, UK). Real-time quantitative PCR (qPCR) reactions were 
run using cDNA with a Runx1 quantitect primer assay (Amplicon length-120bp, 
Mm_Runx1_1_SG QuantiTect Primer Assay [QT00100380], Qiagen, UK) and SYBR green 
mastermix (Applied Biosystems, UK) or with a Runx1 Taqman Gene Expression Assay 
(Amplicon length 81bp, Mm01213404_m1) and Taqman Univeral Mastermix Mix II, no UNG 
(both ThermoFisher Scientific, UK) in a 20 µL final volume or 10 µL final volume respectively 
with the following cycling conditions: hold for 2 min at 50°C followed by 10 min at 95°C to 
heat-start the Taq polymerase enzyme, then 40 cycles of 95°C for 10 min, 60°C for 1 min. 
Relative mRNA levels were analysed using comparative Ct calculations; either 2-ΔΔCt 
(regional comparisons relative to RV region) or 2-ΔCt (whole heart or cardiomyocytes) 
normalised to Gapdh (whole heart; Eurofins MWG Operon, Germany), or Gapdh Taqman 
Gene Expression Assays (Amplicon length 109 Mm99999915_g1, ThermoFisher Scientific, 
UK) or Peptidylprolyl Isomerase B; PPIB (isolated cardiomyocytes).  
 
Generation of mice with conditional cardiomyocyte-specific gene excision of Runx1 
We generated cardiomyocyte-specific Runx1-deficient mice using standard Cre-LoxP-based 
gene targeting strategies (Supplemental Material Figure 5). This approach utilized mice with 
LoxP sites flanking exon 4 of the Runx1 gene (Runx1fl/fl) and mice with the cardiac-specific 
alpha-myosin heavy chain (MHC) promoter directing expression of a tamoxifen-inducible Cre 
recombinase (MerCreMer) to adult cardiomyocytes1. Cardiomyocyte-specific excision of 
Runx1 was induced in adult mice by a single i.p. injection of tamoxifen (40 mg/Kg) to prevent 
cardiac dysfunction arising from repeated injections2. 
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Genomic PCR was performed to determine the specificity of the Runx1 gene disruption 7 d 
after injection with tamoxifen (Supplemental Material Figure 5A–C). Excision of exon 4 
(denoted by the PCR product presenting at approximately 310 bp following gel 
eletrophoresis) was clearly present in all male and female mice. However, this size PCR 
product was absent in control Runx1fl/fl mice, which instead produced only a 275 bp PCR 
product, denoting insertion of the LoxP sites. Control Runx1wt/wt mice exhibited only a 203 bp 
PCR product representing an unaltered Runx1 gene as expected. To determine the extent to 
which the Runx1 gene had been excised from cardiomyocytes, PCR of genomic DNA was 
performed on both: (i) whole hearts and (ii) cardiomyocytes that had been separated from 
other cell types by plating and short term culture or by FACS (Supplemental Material Figure 
5C). Isolated cardiomyocytes exhibited an increased ratio of the excised PCR product (310 
bp) to the combined excised (310 bp) and LoxP product (275 bp) indicating approximately 
~50% Runx1 gene excision (Supplemental Material Figure 5C).  
Whilst the mRNA Runx1 levels were significantly reduced in whole heart tissue taken from 
the right (RV) and left ventricle (LV) of Runx1Δ/Δ mice compared to control mice (Runx1wt/wt 
and Runx1fl/fl) 4 wk post-MI, this was not the case in the border zone (BZ) and infarct (INF) 
regions reflecting the increased number of non-cardiomyocytes in these regions post-MI 
(Supplemental Material Figure 5D). 
At 2 wk post-MI, mRNA Runx1 levels (relative to the house keeper gene Peptidylprolyl 
Isomerase B; PPIB) in cardiomyocytes isolated from Runx1Δ/Δ mice were 61% of the control 
mice (Runx1fl/fl) (0.055±0.006 vs. 0.090±0.012 (2-Δct); P<0.05; Supplemental Material Figure 
5E) and Runx1 protein levels in cardiomyocytes isolated from Runx1Δ/Δ mice were 48% of 
the control mice (Runx1wt/wt and Runx1fl/fl) (47.6±9.6 vs. 100±3.84% change; P<0.05; 
Supplemental Material Figure 5F) indicating that protein and mRNA expression correlates 
with the level of gene excision in these cells.  
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PCR of genomic DNA 
Mice were killed by the schedule one procedure. Hearts were removed and perfused via the 
aorta with saline solution to wash out the blood before being snap frozen in liquid N2 and 
stored at –80˚C. The tissue was homogenized with the TissueLyser system (QIAGEN) using 
a stainless steel bead in each sample. Tissue was disrupted mechanically in proprietary lysis 
buffer (Illustra Nucelon Genomic DNA Extraction kit, GE Healthcare) until no visible pieces 
of tissue remained (~2 min at 25 oscillations/s). Lysates were incubated for at least 3 h with 
proteinase K at 50˚C. DNA was extracted according to the manufacturer’s instructions. 
Primers used were as described by Chen et al. 3: Runx1 forward primer WT and floxed 
alleles (Ex4Int – F563) 5’- CCC ACT GTG TGC ATT CCA GAT TGG -3’; Runx1 reverse 
primer for WT and floxed alleles (Ex4 – R837) 5’- GAC GGT GAT GGT CAG AGT GAA GC -
3’; and Runx1 reverse primer for deleted floxed allele (Int3-2) 5’- CAC CAT AGC TTC TGG 
GTG CAG -3’. Herculase II Fusion DNA polymerase (Agilent) was used under the following 
stepwise cycling conditions: 
1  95°C 1 min  
2  95°C 20 s 
3  58°C 20 s 
4  68°C 1 min 
5  Repeat steps 2–4, 30 times 
6  68°C 4 min 
7  12°C hold 
 
RNAscope® assay 
RNA in situ hybridization was performed using the RNAscope® duplex kit (Red/Brown) 
(Advanced Cell Diagnostics) on the Leica Bond Rx Autostainer to detect Runx1 and PCM-1 
using mouse-specific probes (Advanced Cell Diagnostics) on formalin fixed paraffin 
embedded (FFPE) mouse hearts. PCM1 has been shown to be 95-99.9% specific to 
cardiomyocytes furthermore, cardiomyocytes could be identified morphometrically by their 
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elongated nucleus and/or the presence of surrounding muscle striations4-6. Adult mouse 
hearts at 1 and 14 day post-MI and SHAM FFPE were cut at 4 μm and placed in an oven 
60°C for 1 h. The duplex staining protocol was performed following the manufacturer’s 
(Advanced Cell Diagnostics) strict guidelines. For each heart, positive (PPIB and POLR2A) 
and negative controls (bacterial dapB) were run (Supplemental Material Figure 1). The 
images were visualized on a brightfield Evos Cell Imaging microscope. Cells were 
considered to be positive if at least one brown (PCM-1) or red (Runx1) punctate dot was 
present within the nuclei - a single punctate dot representing a single mRNA transcript7. 
Cells were manually counted for quantification as previously described7 taking three 
representative images per region of the heart on mid-heart sections where the aorta is 
confluent with the LV chamber. 
 
Pressure–volume loop measurements 
Pressure–volume (PV) loop measurements were recorded using the Transonic ADV500 
small animal model PV measurement system or a Scisense PV loop system and a 1.2 F 4.5 
mm spaced PV admittance catheter (FTH-1212B-4517, Scisense, UK) as previously 
described8. Mice were anesthetized in a pre-filled induction chamber with 4% isofluorane 
gas (Isoflo, Abbott Laboratories, USA) delivered in O2 at 1.5 L/min. Mice were 
endotracheally intubated and maintained with artificial ventilation at 120 breaths/min with a 
tidal volume of 120 µL. Isofluorane concentration was gradually reduced to 1.5% during the 
procedure and maintained at this level for the duration of the measurements. The 
temperature was maintained at 37ºC by a homeothermic monitoring system (Harvard 
Apparatus, UK). A longitudinal incision was made in the center of the neck and the right 
carotid artery dissected free of the surrounding tissue. A small incision was made in the 
vessel and the catheter inserted into the vessel and advanced into the left ventricle of the 
heart. Steady state readings were then taken for 15 min. Data were recorded in the 
Labscribe software via a four-channel analog-to-digital converter. Data were analyzed offline 
by averaging the final 2 min of steady state recording. 
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Echocardiography 
Mice were anesthetized as for pressure–volume loop measurements and maintained via 
facemask on 0.5-1% isofluorane in 1.0 L/min O2.   
 
Histology 
Hearts from killed animals were fixed for a minimum of 24 h in 10% neutral buffered formalin 
(CellPath, UK) after which time they were embedded into a wax block for sectioning. Each 
heart was sliced parallel to the long axis every 200 µm to produce 4 µm serial sections. At 
every 200-µm interval, picrosirius red was used to stain collagen until the mid-point depth of 
the heart (defined by the largest ventricular cavity size and confluence of the LV chamber 
with the aorta). Quantification of regional areas and infarct size was performed on each 
section using Image J and Adobe Photoshop CC 2015 and mean data per heart were 
generated as described in previous studies9. The point at which the infarct region became 
50% of muscle and 50% of collagen (as determined using picrosirius red staining) was 
denoted as the BZ in histological sections. Infarct thickness was defined and measured as 
the distance between the endocardium and epicardium of the infarcted myocardium. This 
was performed using three lines drawn perpendicular to the curvature of the ventricular wall 
and the distance measured with ImageJ on each histological section. Cardiomyocyte size 
was assessed by staining adjacent sections at the level of the middle of the heart with 
AlexaFluor-594 conjugated wheat germ agglutinin (WGA; Invitrogen, Paisley, UK). Briefly, 
de-waxed and rehydrated sections were boiled in sodium citrate buffer for 10 min, followed 
by blocking in 1% BSA/PBS with 5% goat serum for 1 h. Sections were then incubated with 
10 µg/mL WGA for 1 hr at room temperature in the dark. Sections were mounted in ProLong 
Gold with DAPI (Invitrogen, Paisley, UK). Confocal imaging was used to produce an image 
of the LV and septum from each heart. A digital grid was placed on the image using ImageJ 
and grid intersections determined which cardiomyocytes where then chosen for 
measurement of cell length, diameter (perpendicular to centre of longest axis) and cross-
sectional area (thus avoiding cell selection bias). 
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Infarct size at 24 h post-MI and I/R injury. 
Infarct size in the mouse MI model was determined using triphenyltetrazolium chloride (TTC) 
(dissolved at 1% in a phosphate buffer for 15 min [37°C]) to detect viable tissue in x5 
transversely cut myocardial slices per heart. In the mouse I/R model, the area at risk (AAR) 
and infarct size was measured using previously published protocols10 whereby 1% Evans 
blue delineated the area not at risk, TTC the viable tissue and infarct region white. Heart 
slices were then placed into 10% neutral buffered formalin for 20 min at room temperature. 
Digital photographs of the myocardial sections from each heart were laid onto a white 
background and whole photograph white balanced against the background using Adobe 
photoshop. The number of pixels of each region was counted using Image J (National 
Institute of Health, Maryland, USA) and expressed as relative %. 
 
Adult cardiomyocyte isolation 
Hearts were removed and the coronary arteries perfused via the aorta at 4.0 mL/min (37°C) 
with a Modified Isolation Krebs–Henseleit (MIKH) solution for 4 min. The composition of 
MIKH (in mmol/L) was: NaCl (120.00), KCl (5.40), HEPES (20.00), NaH2PO4 (0.52), 
MgCl26H2O (3.50), taurine (20.00), creatine (10.00), glucose (11.10). The pH was adjusted 
to 7.4 with NaOH. Perfusion of hearts with MIKH was followed by perfusion with MIKH 
containing 1.0 mg/mL of type I collagenase (Worthington Biochemical) and 0.1 mg/mL of 
type XIV protease (Sigma-Aldrich). After ~6 min, the enzymes were removed and the heart 
perfused with MIKH containing 0.7% BSA (Sigma-Aldrich) but no enzymes for a further 4 
min. The left ventricular free wall was then cut into strips and mixed to yield a single-cell 
suspension in MIKH containing 0.7% BSA. The calcium concentration in solution ([Ca2+]o) 
was raised in this suspension via stepwise increments until 1.0 mmol/L was reached. 
 
Immunoblotting 
Isolated cardiomyocytes were lysed in radioimmunoprecipitation assay (RIPA) buffer. The 
composition of the RIPA buffer (in mmol/L) was: Tris (20), NaCl (150), EDTA (5), EGTA (5), 
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DTT (1) plus 1.0% Triton X-100 and 0.5% deoxycholate. MI tissue samples in Supplemental 
Material Figure 2 were disrupted in extraction buffer (0.1 M Tris–HCl, 0.01 M EDTA, 0.04 M 
DTT, 10% SDS, pH 8.0) using an ultrasonic device. Protease inhibitors added (in mmol/L) 
were: Na pyrophosphate (2.5), β-glycerophosphate (1.0), Na3VO4 (1.0), PMSF (1.0), NaF 
(2.0), plus 10 µg leupeptin, one tablet of a protease inhibitor cocktail (Complete Mini, Roche, 
Germany) and one tablet of phosphatase inhibitor (Phos-stop, Roche, Germany) per 10 mL 
buffer. The buffer was adjusted to pH 7.4. Lysates were assayed for protein concentration 
using the bicinchoninic acid assay. BSA was used to produce a standard curve. Samples 
were mixed with β-mercaptoethanol as the reducing agent and a loading dye before heating 
at 99˚C for 90 s. The lysates were loaded at a concentration of 10 µg per well into 4–12% 
Bis-tris gels (NuPAGE, Life Technologies, UK) with 4 µg of lysed thymus tissue as a positive 
control. Electrophoresis conditions were 75 V for 10 min followed by 165 V for 60–90 min. 
Protein was transferred to 0.45 µm pore size nitrocellulose membranes (Life technologies, 
UK). 
 
Membranes were incubated overnight at 4˚C with primary antibodies against: PLB A2 
(1:1000; MA3-922, Pierce), Runx1 (1:500; ab35962, AbCam), p-PLB Ser16 and p-PLB 
Thr17 (1:1000; A010-12 and A010-13, Badrilla), PKCα (1:200; sc-8393, Santa Cruz), PP1 
(1:200; sc-7482, Santa Cruz). Pan-actin (1:1000; 4968s, Cell Signalling) or Red Alert 
Western blot stain (Merck Millipore) were used as loading controls. Secondary antibodies 
were donkey anti-mouse IRDye 800 CW and donkey anti-rabbit IRDye 680RD (1:10000; 
926-32212 and 926-68073, Li-Cor). Western blots were visualized and quantified using a LI-
COR fluorescence imager and LI-COR or Quantity One analysis software. Figure 5A, 5D 
and 5G are separate blots but have been cut and probed separately for each different target. 
Same lanes were used for Runx1wt/wt MI mice in Figure 5D hence the actin signal is common 
to both PKC and PLB. 
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Epifluorescence measurements of field stimulated calcium transients 
Isolated cardiomyocytes (1.8 mmol/L [Ca2+]o) were loaded with calcium–sensitive 
fluorophore (5.0 µmol/L Fura-4F AM, Invitrogen). Cardiomyocytes were incubated in MIKH 
for 30 min for de-esterification in a cell bath (Cell Microcontrols) followed by superfusion with 
MIKH at 37°C and field–stimulation (1.0 Hz, 2.0 ms duration, stimulation voltage set to 1.5 x 
threshold). Caffeine (10 mmol/L, 20 s; without field stimulation) was applied before the 
protocol. Field-stimulation was started after 10 s of perfusion with MIKH and sustained for 
120 s before application of a second caffeine bolus at the end of the protocol. The Fura-4F 
fluorescence ratio (340/380nm excitation; R340/380nm) was measured using a spinning wheel 
spectrophotometer (Cairn Research Ltd.; sampling rate of 5.0 kHz) to measure the intra-
cardiomyocyte [Ca2+]i. Cell-edge detection (IonOptix) was used to measure cell length. Data 
were analyzed offline. The mean Fura-4F fluorescence ratio was obtained by averaging 12 
steady state transients (Origin) and converted to [Ca2+]i as previously described11. Particular 
experiments utilized pretreated (30 min) and perfusion with the PKA inhibitor H89 (1 µmol/L; 
Tocris Biosciences, Bristol UK) as previously described12. 
 
Determination of the in vivo electrocardiogram (ECG) in Runx1Δ/Δ and control mice 2 
wk-post-MI.  
Mice were anaesthetised and maintained at 1 % isoflurane in 1 L/min O2. ECG was recorded 
with an IX-228/S data acquisition unit and LabScribe2 software (iWorx) using 3 electrodes, 
placed subcutaneously in the right forelimb, left forelimb and right hindlimb. The ECG was 
recorded for 5 min, traces analysed with Labscribe3 software (iWorx) and the last 20 s of the 
traces were used to determine the PR and QT intervals, averaging every 30 beats. The QT 
interval was corrected for heart rate (QTc), calculated using the QT and RR intervals with the 
Bazett’s formula, adjusted for mice: QTc = QT/(RR/100)0.5. 
The QT interval (which coincides well with the action potential duration; APD13) increased 
between sham and MI mice in both groups as expected13, but there was no significant 
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difference in QT interval between control and Runx1D/D mice post-MI (Supplemental Material 
Figure 9A&B). 
 
Determination of the action potential duration in cardiomyocytes isolated from 
Runx1Δ/Δ and control hearts 2 wk-post-MI.  
Voltage recordings were made on isolated cardiomyocytes using the CellOPTIQTM  
electrophysiology platform (Clyde Bioscience Ltd., Glasgow, UK). Cells were loaded with 
8 µmol/L Di-4 ANEPPS, and illuminated using a 470nm OptoLED (Cairn Research; 
Faversham, UK). The APD was measured at a range of lengths (APD20, 40, 60 and 80) and 
demonstrated no significant difference between control and Runx1D/D mice post-MI. Together 
with the ECG measurements above, the experiments demonstrated that an increased APD 
cannot account for the changes in Ca2+ handling between control and Runx1D/D mice post-MI 
(Supplemental Material Figure 9C&D). 
 
Determination of calcium entry in cardiomyocytes isolated from Runx1Δ/Δ and control 
hearts 2 wk-post-MI.  
Fura-4F (8 µmol/L)-loaded cardiomyocytes were alternately excited between 360 and 
380nm with emission collected at 510nm and electrically paced using field stimulation 
(2ms, 40V, 1Hz). Two previously published protocols were used to measure the amplitude 
of the Ca2+ transient in the absence of SR Ca2+ release (an index of Ca2+ influx via the L-type 
Ca2+ channel). The first protocol measured the amplitude of the first stimulated Ca2+ 
transient immediately after application of 10mM caffeine (to empty Ca2+ from the 
sarcoplasmic reticulum; SR)14, 15 (Supplemental Material Figure 9E&F) and in separate 
experiments, the second protocol measured the amplitude of the stimulated Ca2+ transient 
during inhibition of the SR with thapsigargin (1µmol/L for 30 min; Supplemental Material 
Figure 9G)16. Both protocols confirmed that there was no change in the amplitude of Ca2+ 
influx between control and Runx1D/D mice post-MI. Collectively, these experiments 
12 
 
demonstrated that an increased Ca2+ entry cannot account for the changes in Ca2+ handling 
between control and Runx1D/D mice post-MI. 
 
Viral overexpression of Runx1 in culture 
Adult rabbit cardiomyocytes were isolated as described above but in sterile filtered isolation 
MIKH. The [Ca2+] in solution ([Ca2+]o) was raised in this suspension via stepwise increments 
until 1.0 mmol/L was reached. Cardiomyocytes were gently centrifuged in a hand-operated 
centrifuge and resuspended in prewarmed minimal essential media (MEM; Life 
Technologies) supplemented with L-glutamine and penicillin–streptomycin plus 10% fetal 
calf serum (FCS). The cells were added to wells of a 6-well tissue culture plate at a density 
of 1 x 105 rods per well and incubated at 37˚C in 5% CO2 for 1–2 h to allow the 
cardiomyocytes to adhere to the base of the well. The media was carefully aspirated under 
sterile conditions. Freshly warmed MEM without FCS was added to each well. Adenovirus 
was previously prepared with cloned genes for GFP (control Ad-GFP) or Runx1 with GFP 
(experimental Ad-Runx1) using standard protocols17, 18. Aliquots of each virus were thawed 
and diluted to 1:100 with warmed MEM. The PFU of each virus was 2.54 x 1010 for Ad-
Runx1 and 1.10 x 1011 for Ad-GFP. The volume of the virus required for infection was 
calculated based on the number of rod-shaped cardiomyocytes and the PFU of the virus. 
Cultures were maintained at 37˚C in 5% CO2 for 24 h.  
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Supplemental Material Figure 1. Control RNAscope probes. Typical control heart section 
images of (A) negative dapB and (B) positive PPIB and POLR2 probes taken from the right 
ventricle (RV), left ventricle (LV), border zone (BZ) and infarct (INF) regions in MI hearts 1 
day post-MI or the equivalent regions in sham hearts.  
 
Supplemental Material Figure 2. Runx1 expression in WT C57BL/6 mice post-MI. (A) 
Typical PV loop traces at 4 weeks post-MI and mean data (n=10 sham, n=13 MI; *P<0.05, 
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Student’s t-test) for; (B) Left ventricular (LV) End-systolic pressure, (C) maximum rate of 
contraction, (D) LV end-diastolic pressure, (E) maximum rate of relaxation, (F) LV end-
systolic volume, (G) LV end-diastolic volume and (H) Ejection fraction. (I) Whole heart 
Runx1 mRNA (n=6 sham, n=7 MI; *P<0.05, Student’s t-test). (J) MI heart (BZ,border zone; 
LV,left ventricle; INF,infarct; RV,right ventricle; Scale=1mm). (K) Regional Runx1 mRNA 4 
wk post-MI (n=4 sham, n=8 MI). #P<0.05 relative to RV and *P<0.05 sham versus MI, 
Student’s t-test. (RQ,relative quantification). (L) Regional Runx1 protein 3 wk post-MI (n=5), 
with (M) mean data (ANOVA).  
 
Supplemental Material Figure 3. Regional Runx1 mRNA 8 wk post-MI 
Runx1 mRNA in different regions (INF, infarct; BZ, border zone and LV, left ventricle) of 8 wk 
post-MI hearts (n=4 sham, n=6 MI; *P<0.05 Student’s t-test). 
 
Supplemental Material Figure 4. Echocardiography study – cardiac contractile 
function in C57Bl/6J mice. 1 wk post-MI echocardiography study measuring fractional 
shortening in WT C57Bl/6J sham (n=3-5) and MI (n=3-6) mice; *P<0.05 Student’s t-test. 
 
Supplemental Material Figure 5. Generation of Runx1Δ/Δ mice. (A) The RUNT domain 
and locations of the three primers (colored arrows) used to detect the Runx1wt/wt, Runx1fl/fl 
and excised Runx1Δ/Δ alleles. LoxP sites are indicated by blue triangles. (B) PCR of genomic 
DNA; whole hearts from male (M) and female (F) mice (Runx1Δ/Δ n=9 for M and n=4 for F; 
Runx1fl/fl n=8 for M and n=6 for F; Runx1wt/wt n=6 for M and n=6 for F). A WT and three-band 
control where used to delineate the appropriate sized bands (bands 1 and 2). (C) PCR of 
genomic DNA; WT and three-band controls (bands 1 and 2), whole heart preparations 
(bands 3–5), cardiomyocytes (CMs) from Runx1Δ/Δ mice that had been separated from other 
cell types by plating and short term culture (band 6) or by FACS (band 7). Mean ± SEM of 
Runx1 excision as denoted by the ratio of the excised band (310 bp) to the combined 
excised (310 bp) and LoxP band (275 bp) (band 5 [n=3], band [n=4)] and band 7 [n=2]), 
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*P<0.05 ANOVA. (D) Runx1 mRNA levels (relative to PPIB; 2-ΔCt) in whole heart tissue from 
the right ventricle (RV), left ventricle (LV), border zone (BZ) and infarct (INF) regions of 4 wk 
post-MI hearts (Runx1Δ/Δ MI [n=5 hearts] as % of Runx1wt/wt and Runx1fl/fl MI [n=9 hearts] 
*P<0.05 Student’s t-test). (E) Runx1 mRNA levels (relative to PPIB; 2-ΔCt) in cardiomyocytes 
separated from other cell types by plating and short term culture from 2 wk post-MI hearts 
(Runx1Δ/Δ MI [n=7 hearts] as % of Runx1fl/fl MI [n=8 hearts], *P<0.05 Student’s t-test). (F; 
Left) Western blot of Runx1 in isolated cardiomyocytes from 2 wk post-MI hearts with pan-
actin loading control (performed on same blot as Figure 6A) and thymus (Thy) positive 
control for Runx1. (F; Right) Percentage change in Runx1 protein in isolated 
cardiomyocytes from 2 wk post-MI hearts (Runx1Δ/Δ MI [n=5 hearts] as % of  Runx1wt/wt and 
Runx1fl/fl MI [n=5 hearts], *P<0.05 Student’s t-test).  
 
Supplemental Material Figure 6. Blinded study – cardiac function assessed by 
echocardiography in Runx1Δ/Δ mice. 2 wk post-MI blinded study (control Runx1fl/fl MI 
(n=8), Runx1wt/wt MI (n=11) and Runx1Δ/Δ MI (n=7), *P<0.05 ANOVA) for the following 
functional parameters: (A) Fractional shortening (FS), (B) Left ventricular internal diameter 
at systole (LVIDs), (C) LVID at diastole (LVIDd), (D) LV posterior wall thickness at systole 
(LVPWs), (E) LVPW thickness at diastole (LVPWd). 
 
Supplemental Material Figure 7. Echocardiography study – cardiac contractile 
function in Runx1Δ/Δ mice. 1 wk post-MI echocardiography study measuring fractional 
shortening in Runx1Δ/Δ MI (n=5-6) and control Runx1fl/fl MI and Runx1wt/wt MI mice combined 
(n=5-10); *P<0.05 Student’s t-test. 
 
Supplemental Material Figure 8. Infarct size at 24 h post-myocardial infarction (MI) and 
post-ischemia reperfusion (I/R). (A) Typical heart section images of MI using TTC 
staining. (B) Mean infarct area (IA) as % of left ventricle (LV) [control MI (n=8) and Runx1Δ/Δ 
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MI (n=5), *P<0.05 Student’s t-test]. (C) Typical heart section images of IR using TTC 
staining. (D) Mean area at risk (AAR) as % LV (left) and IA as % of AAR (right) [control MI 
(n=6) and Runx1Δ/Δ MI (n=4), *P<0.05 Student’s t-test]. Scale bar: 1mm Linear adjustment of 
contrast, brightness or color were applied equally to all parts of the image. 
 
Supplemental Material Figure 9. Isolated cardiomyocyte electrical activity in Runx1Δ/Δ 
mice. (A) Typical electrocardiogram (ECG) traces from control and Runx1Δ/Δ and mice 2 wk-
post-MI with (B) mean QT and QTc (corrected) intervals of control Runx1fl/fl and Runx1wt/wt 
mice combined (n=4 sham; n=10 MI) and Runx1Δ/Δ (n=4 sham; n=6 MI), *P<0.05 Student’s t-
test. (C) Typical voltage recordings on isolated cardiomyocytes from control and Runx1Δ/Δ 
and mice 2 wk-post-MI with (D) mean action potential duration (APD) at a range of lengths 
(APD20, 40, 60 and 80) of control Runx1fl/fl MI and Runx1wt/wt MI mice combined (n=28 
cardiomyocytes, 6 hearts) and Runx1Δ/Δ MI (n=18 cardiomyocytes, 5 hearts). (E) Typical 
calcium measurements of the Ca2+ transient in the absence of SR Ca2+ release in isolated 
cardiomyocytes from control and Runx1Δ/Δ and mice 2 wk-post-MI with (F) mean amplitude 
of the first stimulated Ca2+ transient immediately after application of 10mM caffeine of control 
Runx1fl/fl MI and Runx1wt/wt MI mice combined (n=31 cardiomyocytes, 7 hearts) and Runx1Δ/Δ 
MI (n=11 cardiomyocytes, 3 hearts). (G) Mean amplitude of the stimulated Ca2+ transient 
during thapsigargin-mediated SR inhibition of control Runx1fl/fl MI and Runx1wt/wt MI mice 
combined (n=6 cells; 2 hearts) and Runx1Δ/Δ MI (n=5 cells; 2 hearts). 
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